 ALPHARETTA, Ga., Jan. 12, 2021 GLOBE NEWSWIRE -- Clearside Biomedical, Inc. NASDAQ:CLSD, a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the first patients have been enrolled in its Phase 12a clinical trial of CLS-AX axitinib injectable suspension in patients with neovascular age-related macular degeneration wet AMD. Clinical sites, all based in the United States, are activated and currently screening wet AMD patients for this Phase 12a trial, known as OASIS, involving CLS-AX, a proprietary suspension of axitinib for suprachoroidal injection. 